Anavex Life Sciences Corp (AVXL)

[falconer66a]

Duel Administration of Both Anavex Drugs

What about a3-71 and a2-73 as a combination drug?

Well, that combination would be, for me, a prime therapeutic goal; something to be focused on. First, of course, in transgenic murines (lab rats, with inserted genes of human central nervous system diseases; then, as quickly as possible, in human trials.

Why? The safety and multiple efficacies of Anavex 2-73 are so clearly established in transgenic murines that the three consequent human trials are proceeding, Rett syndrome (a 15-n, short human trial), Parkinson’s disease, and the final full-scale Altzheimer’s clinical trial involving 450 Australians.

But, then, what about Anavex 3-71? Simply, it either parallels or exceeds the positive therapeutic outcomes of Anavex 2-73 for various, multiple CNS diseases (and very likely others, where mitochondrial dysfunction is causative or complicating). A bit of the unique therapeutic traits of Anavex 3-71 are touched upon here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390529

But do one’s own diligence on the subject. In a browser read what comes up with this search:
anavex 3-71 advantages

Combining both of these powerful Anavex sigma-1 receptor agonists is likely to yield, at least, the favorable outcomes of one of the two. In combination there may well be a therapeutic synergy, where 1 + 1 = >2.

It’s not something difficult to assess with murines. I’m certain that Anavex Life Sciences Corp has data on such trials; but holding them for propitious revelation sometime in the future — perhaps after positive, confirming results emerge from any of the three human Anavex 2-73 trials underway.

Might all of this be clinical gamesmanship by Dr. Missling, setting in place some really spectacular murine results to be released after the three clinical trials establish Anavex 2-73 safety and efficacies in real humans? The big headlines from those, later this year, will be in the nature of, “New Anavex Drug Demonstrates Safety, Efficacy Against Three CNS Diseases.”

That will be really great. But what will be the results of a consequent media release by Anavex with a paragraph lead such as this:

“Anavex Life Sciences Corp is extremely pleased with the very positive therapeutic results Anavex 2-73 has proven in three clinical trials. We will now move forward with new clinical trials for a number of diseases caused by or involved with mitochondrial and autophagy dysfunctions. We have extensive murine data showing that duel administration of both Anavex 2-73 and Anavex 3-71 yields remarkable preventions and resolutions of a wide variety of human diseases with those involvements. We see this duel drug administration taking Anavex Life Sciences Corp to an even greater role as a major pharmaceutical corporation, treating or preventing an ever-wider diversity of diseases and conditions — as demonstrated in our extensive studies with transgenic murines.”